AstraZeneca Records Earnings from COVID-19 Vaccine

AstraZeneca Records Earnings from COVID-19 Vaccine

As the globe learns to live with the virus, AstraZeneca (AZNL) said it will begin to generate minimal profit on its coronavirus vaccine, and the company is in talks with several governments about further orders for delivery next year.

The Anglo-Swedish company during the pandemic had earlier said the vaccine being developed with Oxford University would be at a cost, recently added that low-income countries would continue to receive the vaccine at no profit basis, while a commercial approach would be applied to new orders in the post-pandemic period.

The vaccines contributed one cent to the company’s core earnings resulting in a 14 percent increase. According to the Chief Executive, Pascal Soriot, overall product sales increased by 49% to $9.74 billion, with vaccination sales surpassing $1 billion.

“This project was initiated with the intent to help and that it has been doing, and we mentioned that in the future the focus will shift to commercial orders. However, we want to state that at no point will the vaccine be expensive because we intend to keep the vaccination affordable for everyone around the world, “Soriot told pressmen.

Soriot, who noted that the virus was becoming endemic, pointed out that AstraZeneca has announced its intentions to create a new organization whose focus will be on coronavirus and other respiratory disorders as well as coordinate the production and distribution of the vaccine.

He said new orders were being discussed with unspecified countries, primarily for delivery next year, with some prospective customers focusing on booster shots. Adding that despite its not-for-profit model and issues regarding effectiveness, supplies, and links to uncommon blood clots, AstraZeneca’s vaccine has had a bumpy ride, nonetheless, as of the end of September, the pharmaceutical and its manufacturing partner, Serum Institute, had delivered over 1.5 billion vaccine doses world round.

The company AstraZeneca now expects revenues to climb above twenty percent in 2021, including vaccine sales by the end of the fourth quarter.

The Author

Oladotun Olayemi

Dotun is a financial enthusiast who specializes in first-in-class financial content, including crypto, blockchain, market, and business, to educate and inform readers.